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Abstract: Potential progenitor B cell compartments in multiple myeloma (MM) are clinically important. MM B cells and 
some circulating MM plasma cells express CD20, predicting their clearance by treatment with anti-CD20. Here we describe 
two types of clonotypic CD20+ B cell in peripheral blood of myeloma patients, identiﬁ  ed by their expression of CD19 and 
CD20 epitopes, their expression of CD45RA and their light scatter properties. Thus, the circulating component of the MM 
clone includes at least two distinct CD19+ CD20+ B cell compartments, as well as CD138+CD20+ plasma cells. To deter-
mine whether either or both B cell subsets and the CD20+ plasma cell subset were depleted by anti-CD20 therapy, they 
were evaluated before, during and after treatment of patients with rituximab (anti-CD20), followed by quantifying B cell 
subsets over a 5 month period during and after treatment. Overall, all three types of circulating B lineage cells persist despite 
treatment with rituximab. The inability of rituximab to prolong survival in MM may result from this failure to deplete 
CD20+ B and plasma cells in MM.
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Introduction
The malignant clone in multiple myeloma is complex and highly heterogeneous in the bone marrow 
and the blood. Although myeloma plasma cells cause most pathological symptoms and are the only 
compartment of the malignancy that is routinely monitored during treatment, earlier B lineage compart-
ments persist throughout therapy and are likely sources of relapse. In multiple myeloma, the clonotypic 
IgH VDJ gene rearrangement provides a unique molecular signature that remains constant throughout 
the course of disease. Other genetic and/or molecular signatures characterize MM, but these are usually 
expressed by only a subset of the MM plasma cells, indicating heterogeneity within the MM clone and 
compromising the use of these signatures as markers to monitor disease burden or to detect presumptive 
progenitor compartments of the disease that escape therapy. The IgH VDJ provides an unequivocal 
marker for all cellular compartments of MM, that is unaffected by any known selective pressures and 
exists independently of differentiation stage, cell morphology, phenotypic characteristics or acquisition 
of more aggressive genotypes.
A variety of work has shown that MM includes clonotypic B lineage cells at stages earlier than the 
compartment of malignant plasma cells in the bone marrow (Bakkus et al. 1994; Bergsagel et al. 1995; 
Pilarski et al. 1996; Szczepek et al. 1997; Szczepek et al. 1998; Pilarski et al. 2000a). Our previous work 
has deﬁ  nitively shown that the peripheral blood of MM patients is colonized by CD19+ clonotypic B cells 
(Szczepek, Seeberger, Wizniak, Mant, Belch, and Pilarski, 1998), as well as by clonotypic IgM+ B cells 
(Reiman et al. 2001; Taylor et al. 2002). The majority of cells in this B lineage compartment of clonotypic 
B cells have a monocytoid light scatter pattern characteristic of large granular cells, phenotypic charac-
teristics of activated lymphocytes (Bergsagel, Masellis, Szczepek, Mant, Belch, and Pilarski, 1995), 
constitutive cytokine synthesis (Szczepek, Belch, and Pilarski, 2001) and migratory properties consistent 
with a compartment capable of mediating malignant spread (Masellis-Smith et al. 1996). The activated 276
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clonotypic B cell compartment is frequent in 
peripheral blood (Szczepek, Seeberger, Wizniak, 
Mant, Belch, and Pilarski, 1998). The characteristics 
of less frequent resting B cell compartments and the 
frequency of clonotypic cells within these compart-
ments remains as yet uncharacterized.
Xenografted peripheral blood cells harboring 
circulating malignant B cells but lacking detectable 
plasma cells are able to xenograft human MM to 
immunodeﬁ  cient mice, as can leukemic plasma cells 
and CD34+ progenitor fractions of MM mobilized 
blood autografts (Pilarski et al. 2002; Pilarski et al. 
2000b; Pilarski and Belch, 2002; Reiman, Seeberger, 
Taylor, Szczepek, Hansen, Mant, Coupland, Belch, 
and Pilarski, 2001). Overall, precursor function within 
the MM clone appears to be complex, involving 
multiple components of the MM hierarchy, including 
both B and plasma cells (Pilarski et al. 2004). This 
concept is supported by recent work from Matsui 
et al. (Matsui et al. 2004) showed that CD34-CD20 
+ MM cell fractions of colony forming cells gave rise 
to engraftment in vivo, who and were sensitive to 
rituximab in vitro. However, the signiﬁ  cance of this 
work is uncertain because no conﬁ  rmation of the MM 
clonotypic signature was carried out. In non-leukemic 
stages of disease, infrequent plasma cells can be 
detected in peripheral blood of MM patients, having 
an apparently abnormal phenotype and monotypic 
light chain expression (Witzig et al. 1993; Witzig 
et al. 1996), but their generative capabilities and their 
clonotypic relationship to MM remain unexplored.
The objective of the current study was to identify 
B cell compartments of the MM clone, determine 
the frequency of clonotypic B cells among their 
normal counterparts, and evaluate the impact of 
rituximab therapy (anti-CD20 serotherapy) on cir-
culating clonotypic B and plasma cells in myeloma. 
Unlike B cells in non-Hodgkin’s lymphoma and B-
CLL, all compartments of CD20+ B lineage cells, 
including a set of circulating CD20+ plasma cells, 
persist throughout rituximab therapy despite their 
medium to high density expression of CD20. This 
suggests that in vivo, antibody targeting by rituximab 
is ineffective against CD20+ clonotypic or presump-
tively clonotypic compartments of the MM clone.
Methods
Patients and samples
After approval from the University of Alberta 
Health Research Ethics Board and informed 
consent, a total of 118 patients with multiple 
myeloma donated heparinized blood samples for 
analysis. Six patients were treated with rituximab 
as previously described (Treon et al. 2002), with 
blood samples for analysis taken pre-treatment, 
prior to each of 4 weekly infusions of rituximab 
and at sequential time points up to 5 months after 
initiating the treatment. Peripheral blood mono-
nuclear cells were prepared as previously described 
(Szczepek, Seeberger, Wizniak, Mant, Belch, and 
Pilarski, 1998) and phenotypically analyzed as 
described in methods.
Reagents
Pan CD19 antibodies were B4-FITC (Coulter Corp. 
(Miami FL) and custom conjugated FMC63-FITC 
prepared from ascites ﬂ  uid as previously described 
(Szczepek, Seeberger, Wizniak, Mant, Belch, and 
Pilarski, 1998). Leu12-FITC (CD19) and CD3-PE 
were from Becton Dickinson (San Jose CA), 
CD138-PE from Immunotec (Marseille France), 
and CD20-PE (B1) from Coulter Corp. Rituximab-
FITC was custom conjugated using aliquots of 
rituximab from the Cross Cancer Institute. 
CD45RA-FITC (FMC44) was custom conjugated 
(Pilarski and Deans, 1993). Isotype controls from 
Becton Dickinson were FITC or PE labeled as 
required. Staining of PBMC with conjugated anti-
bodies and analysis by ﬂ  ow cytometry was as 
previously described (Szczepek, Seeberger, Wiz-
niak, Mant, Belch, and Pilarski, 1998). Neur-
aminidase was from Sigma Aldrich Canada Ltd. 
(Oakville ON). PBMC were treated at 37 
oC for 1 
hour with 0.5 u/ml (100 µl/well), followed by 
washing and staining with the indicated antibodies. 
For molecular analysis, MM PBMC were stained 
with Leu12-FITC and sorted as previously 
described (Szczepek, Bergsagel, Axelsson, Brown, 
Belch, and Pilarski, 1997; Szczepek, Seeberger, 
Wizniak, Mant, Belch, and Pilarski, 1998) to pro-
vide puriﬁ  ed populations of Leu12+ B cells.
A CD19 transfectant was prepared by cloning 
a full-length CD19 cDNA into E. coli XL1- blue 
and transfecting it in CHO-K1 cells (PJ Adamson, 
PhD thesis, University of Adelaide, 2000). Trans-
fectants were stained with CD19 antibodies to 
conﬁ  rm their speciﬁ  city for CD19.
In situ RT-PCR
Clonotypic IgH VDJ sequences for the MM clone 
from each of 15 MM patients were derived and 277
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validated by conﬁ  rming that the selected sequence 
was expressed by the majority of autologous BM 
plasma cells, followed by design and testing of 
patient speciﬁ  c primers annealing to CDR2 and 
CDR3 as previously described (Szczepek, 
Seeberger, Wizniak, Mant, Belch, and Pilarski, 
1998). Sorted FMC63+Leu12+ or FMC63+Leu12− 
PBMC were placed on slides, prepared for in situ 
RT-PCR and then in situ RT-PCR was performed 
as described previously (Pilarski, Giannakopou-
los, Szczepek, Masellis, Mant, and Belch, 2000a; 
Szczepek, Seeberger, Wizniak, Mant, Belch, and 
Pilarski, 1998; Szczepek, Bergsagel, Axelsson, 
Brown, Belch, and Pilarski, 1997). All experi-
ments included speciﬁ  city controls and controls 
for RNA integrity as detailed in previous papers 
(Szczepek, Bergsagel, Axelsson, Brown, Belch, 
and Pilarski, 1997; Szczepek, Seeberger, Wiz-
niak, Mant, Belch, and Pilarski, 1998). The 
number of sorted PBMC expressing the clono-
typic transcripts were compared on a parallel 
slide to the number with transcripts for histone, 
to provide a % value.
Rituximab therapy
Patients were in a previously described cohort 
(Treon, Pilarski, Belch, Shima, Szczepek, Raje, 
Hideshima, Chauhan, Tau, Davies, Preffer, and 
Anderson, 2002). Blood samples were obtained at 
day 0 and day 4 for each cycle of therapy, and at 
monthly intervals after completion of 4 cycles of 
rituximab (10–12 blood samples per patient). 
CD20+ B cells that may have bound rituximab 
remain detectable by their expression of CD19.
Results
Circulating PBMC from MM patients 
include two distinct subsets 
of CD19+ B cells
Previous work has reported the presence of an 
abnormally high percent of B cells (10%–30%) in 
PBMC from patients with MM when detected with 
anti-CD19 mAbs B4 or FMC63 (Bergsagel, 
Masellis, Szczepek, Mant, Belch, and Pilarski, 
1995; Szczepek, Seeberger, Wizniak, Mant, Belch, 
and Pilarski, 1998) but a low % when detected with 
the Leu12 mAb (Kay et al. 1997). To resolve the 
apparent discrepancy, MM PBMC were analyzed for 
CD19 expression using all three mAbs (Fig. 1 and 
Table 1). Figure 1 shows representative PBMC 
from a healthy donor (top row) and from an MM 
patient (bottom row). As previously reported 
(Bergsagel, Masellis, Szczepek, Mant, Belch, and 
Pilarski, 1995; Pilarski, Pruski, and Belch, 2002), 
after staining for the epitopes recognized by anti-
CD19 mAbs B4 and FMC63, a large population 
of B cells was detectable in myeloma patients but 
not in healthy donors. Although it has been sug-
gested that for MM PBMC much of the staining 
with B4 and FMC63 is a serum-related artifact 
(Rasmussen, Jensen, and Johnsen, 2000), no evi-
dence was provided to indicate whether the 
involved cells did or did not express CD19 tran-
scripts, nor whether they expressed IgH transcripts 
and synthesized IgH. In contrast, our previous work 
has clearly shown these cells to express CD19, IgH 
and clonotypic VDJ transcripts (Pilarski, 
Giannakopoulos, Szczepek, Masellis, Mant, and 
Belch, 2000a; Szczepek, Bergsagel, Axelsson, 
Brown, Belch, and Pilarski, 1997; Szczepek, 
Seeberger, Wizniak, Mant, Belch, and Pilarski, 
1998) as well as synthesizing IgH immunoglobu-
lin (Szczepek, Bergsagel, Axelsson, Brown, Belch, 
and Pilarski, 1997), validating their identiﬁ  cation 
as bona ﬁ  de CD19+ expressing B cells, and con-
ﬁ  rming their clonal relationship to autologous MM 
plasma cells. However staining of the same PBMC 
samples with the Leu 12 anti-CD19 mAb detected 
only a small population of B cells in either healthy 
donors or MM patients. Overall, for healthy donors, 
each of the three mAbs detected the same % of 
B cells in any given PBMC sample (6%–7%). This 
was not true for MM patients. Although a compa-
rable % of B cells were detected with FMC63 and 
B4, respectively a mean of 27% or 30% of PMBC, 
Leu12 detected only 2%–7% B cells in MM PBMC. 
Like FMC63/B4+ MM B cells, Leu12+ MM B cells 
escape chemotherapy, remaining detectable during 
and after treatment (Table 1). Two color staining 
with Leu12 and FMC63 revealed two distinct sub-
sets of B cells in MM PBMC, those expressing both 
epitopes, and those expressing only the FMC63 
epitope (Fig. 2); only the former subset is detected 
in PBMC of healthy donors.
All three CD19 mAbs detect CD19 
on CD19 transfectants
To conﬁ  rm that all three preparations of anti-CD19 
mAbs were speciﬁ  c for CD19, stable CD19 CHO 
cell transfectants were stained and analyzed 278
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(Fig. 3). All three mAbs detected CD19 on the 
transfected cells. This analysis further conﬁ  rms 
previous work showing that sorted CD19 MM B 
cells stained with FMC63 express CD19 transcripts 
(Pilarski, Giannakopoulos, Szczepek, Masellis, 
Mant, and Belch, 2000a; Szczepek, Bergsagel, 
Axelsson, Brown, Belch, and Pilarski, 1997).
On MM B cells, an otherwise cryptic 
Leu12 epitope is revealed by
neuraminidase treatment
The Leu12 epitope could be masked by other cell 
surface proteins on MM B cells but not on B cells 
from healthy donors. MM B cells, but not B cells 
from healthy donors, have been shown to express a 
high density of Muc1 (Treon et al. 1999), a branched 
sialoprotein that may obscure some cell surface 
epitopes. To determine whether the apparent absence 
of the Leu12 epitope resulted from masking by the 
Muc1 or other sialoproteins, MM PBMC from three 
patients were treated with neuraminidase, an enzyme 
that cleaves the terminal sugar group and has been 
shown to reveal cryptic epitopes (Tetteroo et al. 
1984). Neuraminidase treatment reveals an other-
wise cryptic Leu12 epitope. A representative patient 
sample is shown in Figure 4. Prior to neuraminidase 
treatment, 8% of the MM PBMC were Leu12+. 
After treatment, 40% of the PBMC were Leu12+; 
these cells co-expressed FMC63, B4, B1 and ritux-
imab epitopes, and the majority had high light scat-
tering properties as described below. The percent of 
MM PBMC expressing FMC63/B4 (CD19) or B1/
rituximab (CD20) epitopes did not change after 
neuraminidase treatment. The same pattern was 
observed for all three treated MM PBMC samples. 
Thus, the use of FMC63, B4 or CD20 antibodies 
allows detection of the aggregate population of 
Figure 1. Expression of CD19 Epitopes on B cell populations in multiple myeloma and in healthy donors: Absence of the Leu12 
epitope on most MM B cells. PBMC from a representative healthy donor (top row of panels) and a representative MM patient (bottom row) 
were stained in two color immunoﬂ  uoresence with CD3-PE and three types of CD19-FITC, B4, FMC63 and Leu12 as indicated in methods. 
The mean values for each antibody are given in Table 1. Files were ungated. Sorted B cells stained as shown here, and sorted within the 
analysis gates shown in this ﬁ  gure have been shown to express intracellular immunoglobulin, CD19 transcripts and IgH transcripts (Pilarski, 
Giannakopoulos, Szczepek, Masellis, Mant, and Belch, 2000a; Szczepek, Bergsagel, Axelsson, Brown, Belch, and Pilarski, 1997) as well 
as clonotypic IgH VDJ (Pilarski, Giannakopoulos, Szczepek, Masellis, Mant, and Belch, 2000a; Szczepek, Bergsagel, Axelsson, Brown, 
Belch, and Pilarski, 1997; Szczepek, Seeberger, Wizniak, Mant, Belch, and Pilarski, 1998).279
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B cells in MM PBMC, including both the Leu12+ cells 
and the Leu12− B cells, without the need to introduce 
neuraminidase. This work conﬁ  rms that both subsets 
of MM B cells are detectable with all three anti-CD19 
antibodies, but that in the absence of enzyme treat-
ment to expose them, Leu12 epitopes are cryptic on 
the large MM B cells. The expression by both subsets 
of rituximab epitopes suggests that they should be 
susceptible to treatment with rituximab.
Leu12+ MM B cells are small resting 
lymphocytes that coexpress CD20 
and CD45RA
Flow cytometry analysis indicated that Leu12+ MM 
B cells have low forward and side scatter properties 
(Fig. 5, left) that are comparable to the known 
light scatter characteristics of healthy donor B 
cells. On average, 83+/−4% of Leu12+ MM B cells 
are small lymphocytes. In contrast, the FMC63+ MM 
B cells include a majority compartment that has 
high forward and side scatter (Fig. 5, right). The 
Leu12+ and FMC63+ (Leu12−) MM B cells also 
differ in their expression of CD20 and CD45RA. 
Multicolor ﬂ  ow cytometry shows that FMC63+ B 
cells include two compartments of B cells, a set 
with a high density of CD20 and high expression 
of CD45RA, and a more frequent set having mod-
erate CD20 expression and dim CD45RA (Fig. 6, 
left panels). The Leu12+ MM B cells have high 
CD20 and high CD45RA (Fig. 6, right panels), 
comparable to that of healthy donor B cells ((Jen-
sen et al. 1989) and not shown). The staining 
proﬁ  le of the Leu12+ B cells indicates that they 
are the same cells that appear as the minority 
compartment of the FMC63+ MM B cells. The 
distinct phenotypic characteristics of the two B cell 
subsets means that combined analysis of CD19 
and/or CD20 with light scatter characteristics pro-
vides useful clinical phenotype to monitor their 
presence in peripheral blood of MM patients.
A proportion of the Leu12+ 
MM B cells are clonotypic
Previous work has shown that the majority of the 
FMC63+ MM B cells express clonotypic IgH VDJ 
and CD19 transcripts (Pilarski, Giannakopoulos, 
Szczepek, Masellis, Mant, and Belch, 2000a; 
Table 1. CD19 epitope distribution on circulating B cells in MM PBMC.
  % of PBMC expressing CD19 Epitopes
Source of PBMC (n)  B4  FMC63  Leu12
Healthy donors (5)  7 ± 4  7 ± 3  6 ± 4
MM patients (12)  30 ± 6  27 ± 5  2 ± 1
Patient PBMC tested at different stages of treatment (n)
†
Diagnosis (6)      3.4 ± 3
Intermittent chemotherapy* (52)      4.1 ± 0.6
Off treatment (29)      6.7 ± 1.7
Terminal disease (10)      2.1 ± 1
Values represent the mean ± SE.
n = number of donors tested.
*For those patients on intermittent chemotherapy, blood samples were taken at least 3 weeks after their last cycle.
†Values for staining with B4 or FMC63 were comparable to those shown in the top section of this table and have been published previously 
(Bergsagel, Masellis, Szczepek, Mant, Belch, and Pilarski 1995); they did not differ among patients at differing stages of treatment.
Figure 2. Two distinct populations of B cells in MM patients.
Respresentative staining of PBMC from a healthy donor and an MM 
patient in two color immunoﬂ  uorescence with Leu12-PE and FMC63-
FITC, showing two distinct populations of B cells in MM patients 
(CD19+ Leu12− and CD19+ Leu12+) but only one in healthy donors 
(CD19+Leu12+). Previous work has shown that the Leu12− popula-
tions detected by B4 and FMC63 are B cells and express clonotypic 
transcripts (Pilarski, Giannakopoulos, Szczepek, Masellis, Mant, and 
Belch 2000a; Pilarski, Szczepek, and Belch 1997; Szczepek, 
Seeberger, Wizniak, Mant, Belch, and Pilarski 1998; Szczepek, 
Bergsagel, Axelsson, Brown, Belch, and Pilarski 1997).280
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average, 18+/−6% of Leu12+ MM B cells are 
clonotypic (range 0%–79%) (Fig. 7). Intriguingly, 
the seven MM patients having fewer than 1% 
Leu12+ B cells in PBMC had the highest propor-
tion that were clonotypic (36+/−13%), while the 
eight MM patients with 1% Leu12 + MM B cells 
in PBMC had a reduced proportion that were clo-
notypic (9+/−3%) (p = 0.01).
Rituximab therapy fails to deplete 
circulating CD20+ MM B cell 
subsets or plasma cells
Previous work has shown that rituximab appears 
to target CD20+ plasma cells in the BM, but oth-
erwise has little clinical impact (Treon, Pilarski, 
Belch, Shima, Szczepek, Raje, Hideshima, 
Chauhan, Tau, Davies, Preffer, and Anderson, 
2002). This and other work shows that both iden-
tiﬁ  ed subsets of clonotypic MM B cells express 
CD19 as well as expressing CD20 at moderate or 
high intensity, suggesting that they should be tar-
geted by rituximab. To determine whether or not 
this was occurring, we analyzed longitudinal 
PBMC samples from 6 patients who had been 
treated with rituximab. B cells were detected by 
staining with both anti-CD20 and anti-CD19 anti-
bodies. For this analysis, CD19/CD20 expression 
and light scatter properties were used as surrogate 
markers to identify the two subsets of clonotypic 
Figure 3. Expression of CD19 epitopes on CD19 transfectants.
To conﬁ  rm that all three antibodies detected CD19 epitopes, FMC63, 
B4 and Leu12 antibodies were used to stain CD19 transfectants. The 
transfectants were shown to express the CD19 epitope as detected 
by binding of each antibody. Appropriate isotype controls were per-
formed for each anti-CD19 antibody. The observed staining with 
Leu12 indicates that in transfectants, unlike MM cells but similar to 
B cells from healthy donors, the Leu12 epitope is exposed.
Pilarski, Szczepek, and Belch, 1997; Szczepek, 
Seeberger, Wizniak, Mant, Belch, and Pilarski, 
1998; Szczepek, Bergsagel, Axelsson, Brown, 
Belch, and Pilarski, 1997); most of these are 
Leu12-. To determine their involvement in the MM 
clone, Leu12+ MM B cells were sorted from 
PBMC of 15 MM patients who were on intermit-
tant chemotherapy or had discontinued therapy. In 
situ RT-PCR was used to determine the number 
having transcripts that were amplified using 
patient-speciﬁ  c primers annealing to CDR2 and 
CDR3 of the clonotypic IgH VDJ sequence. On 
Figure 4. Neuraminidase treatment reveals Leu12 epitopes on 
MM B cells. MM PBMC were treated with neuraminidase (solid line) 
or left untreated (dashed line) as described in methods, followed by 
staining with Leu12-PE. The marker bar indicates staining above 
negative control values. The numerical value above the marker bar 
reports the number of Leu12+ cells after neuraminidase treatment. 
The Leu12
bright peak between 10
2 and 10
3 represents expression that 
is independent of neuraminidase treatment (dotted line), while the 
lower intensity peak represents Leu12 epitopes revealed by neur-
aminidase (solid line). PBMC were also stained before and after 
treatment with ﬂ  uorescent conjugates of FMC63, B4, CD20 mAbs 
B1 and rituximab; the staining proﬁ  les were comparable before and 
after treatment for all antibodies except Leu12.281
CD20+ B and plasma cells persist cells during rituximab treatment
Clinical Medicine: Oncology 2008:2 
MM B cells described above. PBMC were stained 
in two color immunoﬂ  uorescence with both anti-
CD20 and anti-CD19, to ensure detection of any 
B cells whose CD20 epitopes were masked by 
circulating rituximab. Prior to treatment, all 
CD20+ B cells co-expressed CD19. Ten to twelve 
sequential blood samples were analyzed for each 
of the 6 patients treated with rituximab. Pre-
treatment, all B cells in MM PBMC coexpressed 
both CD19 and CD20, as do B cells from healthy 
donors. B cells in MM PBMC were evaluated at 
sequential time points during and after rituximab 
treatment of 6 MM patients. Both large (high 
forward and side scatter properties: monoctytoid 
gates) and small (low forward and side scatter: 
lymphocyte gates) subsets of CD19+ CD20+ B 
cells in MM PBMC, as identiﬁ  ed by either anti-
CD19 (Table 2) or anti-CD20 (Table 3), resist 
serotherapy with anti-CD20. It is interesting to 
note that there was only transient depletion of the 
predominantly normal CD20
hi subset that on aver-
age is only 18% clonotypic. Although patients 
received 4 cycles of rituximab, for most patients 
the % of circulating B cells did not consistently 
decrease over the 5 month study period. Analysis 
was performed before and after each treatment 
with rituximab and then at monthly intervals. For 
both compartments of B cells described above, the 
% of small and large CD20+ cells before, over the 
course of treatment and after therapy is detailed 
in Table 3. Absolute numbers are given in Table 4. 
Based on the speciﬁ  c effects of rituximab on 
B cells, as measured by the % of CD20+ cells in 
PBMC, for all patients a transient decrease was 
detected in one or more samples. However, for 5/6 
patients, the % of CD20+ B cells in both compart-
ments were also transiently or persistently 
increased during and after the therapy. 2/6 patients 
had substantial post-rituximab increases in the 
compartment of small CD20
bright B cells (a subset 
comparable to that shown in Figs. 5 and 6). Fur-
thermore, circulating CD138+CD20+ plasma cells 
were also resistant to four cycles of anti-CD20 
serotherapy (Table 2). When the absolute number 
of B cells was evaluated, taking into consideration 
non-speciﬁ  c changes in the number of lympho-
cytes, there was a minor increase or slight decrease 
in 4/6 patients and a decrease of about 2–4 fold in 
2/6 patients. However circulating B lineage cells 
remained readily detectable in all patients, indicat-
ing the failure of rituximab to clear the majority 
of either the large CD20
med or small CD20
bright 
MM B cells described above, or the CD20+ circu-
lating plasma cells.
Figure 5. Leu12+ B cells have low forward and side scatter, in contrast to FMC63+ B cells which include a subpopulation with high 
forward and side scatter. MM PBMC were stained with Leu12 or FMC63. Files were gated on the CD19+ population for each antibody: 
Leu12+ = 3.3% of PBMC and FMC63+ = 29% OF PBMC. B4+ B cells had the same scatter proﬁ  le as did FMC63+ B cells. B1+ or rituximab+ B 
cells also have a scatter proﬁ  le comparable to that of the FMC63+ B cells. The vertical axis represents side scatter (SSC) and the horizon-
tal axis represents forward scatter (FSC). The horizontal axes from left to right represent increasing extent of forward scatter. The left panel 
shows a single population of Leu12+ B cells having low side and forward scatter. The right panel shows the two subpopulations distinguished 
by FMC63 (FMC63+ high side or forward scatter, and FMC63+ low side or forward scatter).282
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Discussion
This work demonstrates the existence of two dis-
tinct B cell compartments in the peripheral blood 
of MM patients that include cells expressing the 
MM clonotypic signature. Both B cell compart-
ments escape conventional chemotherapy, impli-
cating them in the almost universal relapse that 
afﬂ  icts MM patients. This work shows that they 
also escape treatment with rituximab despite their 
expression of CD20. Previous work has conﬁ  rmed 
the existence of a numerically abnormal B cell 
compartment with an activated B cell phenotype 
and, as shown here, no detectable Leu12 CD19 
epitope. These activated MM B cells express the 
MM clonotypic IgH VDJ clonotypic signature, 
IgH and CD19 transcripts (Pilarski, Giannakopoulos, 
Szczepek, Masellis, Mant, and Belch, 2000a; 
Szczepek, Bergsagel, Axelsson, Brown, Belch, 
and Pilarski, 1997; Szczepek, Seeberger, Wizniak, 
Mant, Belch, and Pilarski, 1998), validating them 
as bona ﬁ  de B cells with intrinsic expression of 
CD19 and clonotypic IgH. MM B cells xenograft 
MM to immunodeﬁ  cient mice (Pilarski, Seeberger, 
Keats, Taylor, Coupland, and Belch, 2002; 
Pilarski, Hipperson, Seeberger, Pruski, Coupland, 
and Belch, 2000b; Pilarski and Belch, 2002). The 
present study shows the presence of an MM B cell 
compartment with a phenotypic proﬁ  le comparable 
to that of healthy donors. However, this pheno-
typically normal B cell compartment includes a 
mean of 18% clonotypic cells, with occasionally 
as many as 79% clonotypic cells, conﬁ  rming a 
relationship with the malignant clone. More clo-
notypic cells are detected among the Leu12+ pop-
ulation in patients with fewer than 1% Leu12+ B 
cells, than are found among those patients 
having 1% Leu12 + B cells. As the aggregate 
number of B cells is reduced by chemotherapy, 
polyclonal populations of presumptively normal 
B cells are preferentially depleted while the malig-
nant MM B cells are preferentially enriched. Our 
previous work also demonstrated significant 
reductions in polyclonal B cells and their func-
tional capabilities (Pilarski et al. 1984; Pilarski 
et al. 1986; Pilarski, Ruether, and Mant, 1985). 
This may explain the observations of Kay et al. 
who found that infectious episodes increased in 
MM patients having low numbers of Leu12+ B 
cells (Kay, Leong, Kyle, Greipp, Billadeau, Van 
Ness, Bone, and Oken, 1997), likely reﬂ  ecting this 
preferential loss of polyclonal B cells. Since poly-
clonal B cells are required to ﬁ  ght infections, their 
relative absence may also partially explain the 
humoral immune deﬁ  ciency in MM (Cone and 
Uhr, 1964) and the reduced levels of polyclonal 
immunoglobulins.
Figure 6. Phenotypic analysis of CD19, CD20 and CD45RA 
identify two distinct populations of CD19+20+ B cells.
Representative MM PBMC were stained with anti-CD19-FITC (hori-
zontal axis) and either CD20-PE vertical axis, top row) or CD45RA-
PE (vertical axis, bottom row). The boxes indicate subopulations 
deﬁ  ned by this analysis. The left top panel shows FMC63+ CD20
Moderate, 
and FMC63+CD20
bright subpopulations, and the left bottom panel 
shows FMC63+CD45RA
bright and FMC63+CD45RA
dim populations. 
The right panels show a single population identiﬁ  ed by Leu12.
Figure 7. A proportion of Leu12+ MM B cells are clonotypic.
FMC63+Leu12− (monocytoid gates) and FMC63+Leu12+ (lymphocyte 
gates) B cells were sorted and analyzed for clonotypic IgH VDJ 
transcripts using in situ RT-PCR. Leu12− monocytoid B cells 
were sorted from PBMC of 12 MM patients. Leu12+ lymphocyic 
B cells were sorted from PBMC of 15 MM patients. Leu12 negative 
B cells included significantly more clonotypic B cells than did 
Leu12+ B cells (p = .003). One of the patients analyzed for clonotypic 
Leu12+ B cells was in a terminal stage of disease.283
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The MM compartment of “activated” B cells 
lacks the Leu12 epitope of CD19. Operationally, 
this means that use of the Leu12 antibody detects 
only the “resting” compartment of circulating B 
cells in MM patients, and excludes detection of the 
majority compartment of clonotypic “activated” B 
cells with monocytoid scatter properties. Neur-
aminidase digestion to remove terminal sialic acid 
residues revealed Leu12 epitopes on these acti-
vated B cells. This may reﬂ  ect expression of sialic 
acid residues on CD19 itself or on neighboring 
proteins such as Muc1, that would otherwise mask 
the Leu12 epitope. Alternatively, neuraminidase 
treatment may alter the surface charge of the cell 
leading to increased exposure of the Leu12 epitope 
to its antibody. Previous work indicated that MM 
B cells having a low scatter proﬁ  le, shown here to 
be Leu12+, had reduced levels of the Muc1 
sialoprotein as compared to the activated set of 
MM B cells (not shown). Furthermore, the acti-
vated clonotypic B cells in MM express the 
CD45R0 isoform (Jensen et al. 1991) which in 
healthy donors identiﬁ  es late stage B cells (Jensen, 
Poppema, Mant, and Pilarski, 1989). In contrast, 
the Leu12 + MM B cells express the CD45RA 
isoform which is also expressed on essentially all 
circulating B cells in healthy donors (Jensen, 
Poppema, Mant, and Pilarski, 1989), further con-
ﬁ  rming that they are resting B cells. In this context, 
they may represent a progenitor population that 
eventually gives rise to malignant MM plasma 
cells, as proposed elsewhere (Pilarski, Reiman, 
Pilarski, Orr, and Belch, 2004).
Given the potential progenitor status of 
CD20+ MM B cells, therapeutic ablation of both 
compartments could be clinically valuable. In 
combination with conventional therapy to target 
the plasma cell compartment in MM bone marrow, 
anti-CD20 might therefore prolong survival. Tar-
geting therapy to the CD20 epitope would be 
expected to deplete both the monocytoid B cells 
which have a moderate density of CD20 and the 
Leu12+ B cells which have a high density of CD20. 
Although Rituximab may deplete CD20+ plasma 
cells resident in the BM (Treon, Pilarski, Belch, 
Shima, Szczepek, Raje, Hideshima, Chauhan, Tau, 
Davies, Preffer, and Anderson, 2002), unexpect-
edly, treatment with Rituximab did not deplete 
circulating CD20
+ B cell compartments in MM 
patients. Our study included phenotyping of every 
patient before and after infusion of rituximab for 
each weekly cycle as well as at monthly samples 
taken at 2–5 months post-treatment (over 10 
sequential blood samples per patient). For all 
patients, transient reductions occurred in the % of 
circulating B cells, but for most patients, the num-
ber of MM B cells transiently or persistently 
increased, with a substantial % of total B cells at 
the end of the study period. Although the ﬂ  ow 
cytometric methods used were not quantitative, 
Table 2. CD19+ B cells and CD138+ plasma cells in MM PBMC resist treatment with rituximab (anti-CD20).
Timepoint (n) % of PBMC
Total CD19+ B cells Total CD138+ PC CD138+20+ PC
Pre-treatment (6) 19.9 ± 4.5 0.4 ± 0.15 0.26 ± 0.14
1–2 months (10) 17.3 ± 2.6
after initial treatment
3–5 months (9) 29.3 ± 6.8
after initial treatment
3–5 months (8) 0.38 ± 0.09 0.23 ± 0.15
after initial treatment
Values represent the mean % ± SE for the indicated subset of PBMC.
n is the number of blood samples analyzed from the 6 patients receiving Rituximab treatment. The values include 1–2 samples per patient, 
averaged for each patient having more than one sample before inclusion in the table, taken within the time window indicated. Absolute 
numbers are provided in Table 4. PC = plasma cells.
PBMC taken from patients that had been treated with rituximab at the indicated time before or after treatment were stained with CD19 
(FMC63), CD20 and CD138 or isotype matched control antibodies. The percent of CD19+ B cells indicted in the table is the aggregate 
number, including both includes both monocytoid and lymphocyte scatter gates. Staining with anti-CD19 was used to ensure detection of 
all B cells including any that had bound rituximab thereby obscuring their CD20 epitopes. Overall, the % of CD19+ B cells was comparable 
to the % of CD20+ B cells (as shown in Table 3) indicating that the extent of surface rituximab binding was likely to be minor. Plasma cells 
were identiﬁ  ed as CD138+ cells with or without concomitant CD20 staining.284
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staining with anti-CD20 includes cells with both 
moderate and high intensity of antibody binding. 
If treatment with rituximab had resulted in a 
reduced density of CD20 epitopes, these cells 
would have been only weakly detectable with the 
methods used. However, this is unlikely to be a 
signiﬁ  cant factor in the present study because 
CD20+ B cell % and the intensity of staining with 
anti-CD20 after treatment were comparable to 
pretreatment values. Based on our phenotypic data, 
rituximab does not reliably deplete circulating 
B cells in MM patients, and by extrapolation would 
not be expected to have an impact on putative MM 
B cell progenitor function. In addition, for 5/6 
patients, CD20
+ circulating plasma cells persisted 
in undiminished numbers for at least 4 months after 
rituximab treatment, indicating their prolonged 
resistance to four cycles of anti-CD20 mediated 
cell killing. The extent to which differing pharma-
cokinetics may inﬂ  uence the impact of rituximab 
therapy and the potential efﬁ  cacy of larger thera-
peutic doses remain unknown. The mechanism(s) 
underlying the failure of rituximab to clear these 
cells may also reﬂ  ect physiological properties of 
the normal and malignant B cells in MM patients 
and possibly resistance to immune effector 
mechanisms shown by others to mediate rituximab 
killing in vitro (Golay et al. 2001; Lefebvre et al. 
Table 3. Population dynamics of lymphocyte and monocytoid CD20+ B cell subsets during treatment with rituximab: 
Percent in PBMC.
A. Lymphocytic B cells (CD20
hi)
Patient Percent of small CD20+ B cells in MM PBMC 
#1 #2 #3 #4 #5 #6
Pre-therapy 7.9 3.2 0.4 0.5 0.9* 5.4
Week 1 0.8 10.2 7.8 2.3 0.1*
Week 2 0.9* 0.5* 1.2 0.1 0.1*
Week 3 0.1* 1.0* 10.1 0.4
Week 4 0.01* 0.02 0.9 0.1*
1 Month 5.1* 8.4 1.4
2 Months 4.1* 4.7 1.3 0.6 0.7
3 Months 8.9* 1.1 0.5
4 Months 11.5 4.6* 10.2 0.2 0.4 0.6
5 Months 57.3
†
B. Monocytoid B cells (CD20
med)
Patient Percent of large CD20+ B cells in MM PBMC 
#1 #2 #3 #4 #5 #6
Pre-therapy 21.9 8.1 31.7 3.6 12.8 7.7*
Week 1 8.6* 22.7 20.0 10.0 14
Week 2 30.1* 4.6 3.6 10.9 14
Week 3 30.4 9.2 29.7 2.8
Week 4 16.8 0.7* 19.6 18*
1 Month 10.7 15.3 1.2
2 Months 23.0 5.3 1.4 16.5 22
3 Months 15.7 3.1 15.7
4 Months 23.5 14.6 20.3 20.3 5.5 15*
5 Months 3.4
PBMC taken at the indicated timepoints before, during and after therapy were stained in separate reactions with anti-CD20 or with anti-CD19 
(FMC63). Files were analyzed for the number of CD20+ cells in the small lymphocyte subset or in the large monocytoid B cell subset.
*Indicates samples in which the number of CD19+ B cells exceeded the number of CD20+ B cells in one or both subsets, likely indicating 
that CD20 epitopes had been hidden by circulating rituximab in vivo. Those samples not indicated by the asterix had comparable numbers 
of B cells as deﬁ  ned by either CD20 or CD19.
†The substantial number of small B cells seen in this sample was also detected by anti-CD19.285
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2006; Treon et al. 2001b; van Meerten et al. 2006). 
Since the density of CD20 appears to be an impor-
tant factor in rituximab mediated cell killing (Golay, 
Lazzari, Facchinetti, Bernasconi, Borleri, Barbui, 
Rambaldi, and Introna, 2001; van Meerten, van 
Rijn, Hol, Hagenbeek, and Ebeling, 2006), at least 
the CD20
bright B cells should have been depleted. 
Despite this, we found that CD20
bright B cells per-
sisted in rituximab-treated MM patients. Rituximab 
has been shown to promote apoptosis in malignant 
cells (Bonavida, 2007; Byrd et al. 2002), but the 
survival of B cells in MM suggests this mechanism 
was not operative. Since rituximab binds to both 
subsets of MM B cells, the failure to deplete them 
may indicate that components of myeloma serum 
protect them from the lytic or apoptotic effects of 
the antibody. The functional capabilities of the MM 
B cells that resist rituximab have not been explored, 
but their persistence over several months suggests 
that they remain viable. It is possible that combina-
tion therapies may enhance the sensitivity to ritux-
imab of persisting B cells. Overall, our observations 
suggest that the impact of rituximab in MM is dif-
ferent from that in lymphoma (Maloney, 2003), 
B-CLL (Cvetkovic and Perry, 2006; Kharfan-
Dabaja et al. 2007) or Waldenstrom’s macroglobu-
linemia (Treon et al. 2001a). In MM, nearly all 
compartments of CD20+ B lineage cells have been 
shown here to resist the toxic effects of this sero-
therapy, providing a plausible explanation for the 
lack of clinical effect for single agent rituximab in 
MM (Treon, Pilarski, Belch, Shima, Szczepek, Raje, 
Hideshima, Chauhan, Tau, Davies, Preffer, and 
Anderson, 2002).
Conclusions
The MM clone includes multiple compartments of 
clonotypic B cells at multiple stages of the pheno-
typically deﬁ  ned B lineage differentiation pathway. 
We have identiﬁ  ed two distinct compartments 
of CD20+ MM B cells, both of which resist 
chemotherapy and are shown here to also resist the 
effects of rituximab. Novel therapeutic strategies 
are needed to target these compartments. Although 
the mechanisms by which rituximab successfully 
depletes lymphoma and other CD20+ malignancies 
do not appear to affect CD20+ B cells or circulat-
ing CD20+ plasma cells in MM, use of other agents 
to target CD20 on the MM B cell compartments, 
for example radiolabeled anti-CD20 (Zevalin) or 
a radiolabeled anti-CD19, might prove useful in 
MM. Because the compartments of the MM clone 
are quite heterogeneous and lack shared vulnera-
bilities, it seems likely that strategically designed 
combinations of two or more therapies will be 
needed to prolong survival by more effectively 
depleting the entirety of the MM clone, inclusive 
of multiple progenitor compartments and end stage 
MM plasma cells.
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